THERAMetrics holding AG (SIX: TMX) announces its 2014 corporate calendar and provides preliminary guidance for its 4th quarter 2013 results

Stans, Switzerland, February 4, 2014 - THERAMetrics Holding AG announces its 2014 corporate calendar and provides preliminary guidance for its 4th quarter 2013 results.

The THERAMetrics Board of Directors confirmed today the dates for its 2014 corporate calendar:

March 18th, 2014:
Elections to the Board of Directors

April 29th, 2014:
Annual General Assembly

August 26th, 2014:
Board of Directors Meeting for the approval of the condensed consolidated interim financial information as per June 30, 2014

Preliminary analysis of the fourth quarter results for the clinical research division indicates a reversal of the trend and a positive EBIDTA value as already forecasted in the November 15th 2013 press release.
Detailed results and analysis will be presented right after the Board of Directors Meeting on March 18th, 2014.

Survey

Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

About THERAMetrics
THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland).

For further information please contact
THERAMetrics holding AG
Investor and External Relations
Tel.: +41 79 285 37 81
[email protected]
www.therametrics.com

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.